Problem

Lila Biologics targets a central problem in next-generation protein therapeutics: designing molecules that bind selectively to solid tumors, deliver a therapeutic payload effectively, remain in the tumor long enough to work, and then clear rapidly enough to reduce exposure to healthy tissue. Its main use case is targeted radioligand therapy for solid tumors, where the clinical challenge is to combine antibody-like targeting with the rapid “in-and-out” pharmacokinetics associated with smaller molecules. The intended benefit is more precise cancer imaging or treatment and, ultimately, better patient outcomes.

The economic pain is the time and capital required to turn a promising protein concept into a developable drug candidate. Lila’s proposition is to compress that discovery process and create differentiated, licensable assets for pharmaceutical partners. The evidence does not disclose quantified market size, pricing, revenue, or development costs; the clearest commercial signal is that Lila produced two development candidates in less than two years and secured a global collaboration with Eli Lilly.

Product / Service

Lila combines an AI-powered protein-design engine with high-throughput experimental discovery and optimization. Its workflow covers de novo binder design, affinity and selectivity optimization, radioligand conjugation chemistry, pharmacokinetic engineering, and formulation or developability work for subcutaneous delivery. The company describes this integrated platform as LILADD and uses it to discover and optimize molecules against a target product profile rather than merely generating binding proteins.

The company has two principal programs: a targeted radiotherapy platform for oncology, based on AI-designed de novo mini-proteins, and a long-acting injectable platform for non-oncology protein therapeutics. The mini-protein approach is intended to provide high target selectivity, strong tumor uptake, and rapid clearance, while the second platform is designed around long-acting, potentially subcutaneous administration. Under the Lilly collaboration, Lila is responsible for designing and developing radioligand development candidates; Lilly is expected to conduct IND-enabling and clinical development and handle commercialization.

Market

Lila competes at the intersection of AI-enabled protein drug discovery, targeted radioligand or radiopharmaceutical therapy, and long-acting biologics. In targeted radioligand therapy, the evidence names ARTBIO as a direct comparator, particularly its PSMA-targeted AB001 small-molecule program. The broader emerging radioligand field includes companies such as Bayer, Convergent Therapeutics, Perspective Therapeutics, PRECIRIX, Ariceum Therapeutics, and Nuclidium, while established radioligand players include Novartis and Telix. Lila’s differentiation is its use of de novo mini-proteins rather than conventional small molecules, peptides, or antibodies.

Lila appears to be a preclinical, pre-revenue biotechnology company rather than a company with an approved product or clinical-stage revenue stream. It publicly launched in September 2025 as a spinout associated with David Baker’s Institute for Protein Design, reported two development candidates, and announced a global, multi-target licensing and research collaboration with Eli Lilly. Lila said it aimed to enter the clinic in 2027; no clinical trial, product revenue, or disclosed financial terms appear in the gathered evidence.